Table 3.
Significant results of comparing aripiprazole with individual D2R antagonists.
| Outcomes | Studies (n) |
Participants (n) |
Effect estimatea | p | I2 | |
|---|---|---|---|---|---|---|
| ARI more favorable than | ||||||
| Haloperidol | Overall symptoms | 3 | 305 | −0.54 (−0.79 to −0.30)SMD | <0.001 | 0% |
| Negative symptoms | 2 | 245 | −0.36 (−0.64 to −0.09)SMD | 0.009 | 0% | |
| Depressive symptoms | 2 | 245 | −0.41 (−0.68 to −0.13)SMD | 0.004 | 0% | |
| All-cause discontinuation | 2 | 494 | 0.77 (0.67 to 0.88)RR | <0.001 | 28% | |
| Discontinuation due to adverse events | 2 | 494 | 0.37 (0.25 to 0.55)RR | <0.001 | 0% | |
| Risperidone | Depressive symptoms | 3 | 331 | −0.32 (−0.53 to −0.10)SMD | 0.005 | 0% |
| Weight gain | 3 | 614 | −0.28 (−0.49 to −0.07)SMD | 0.009 | 35% | |
| Paliperidone | Triglycerides | 2 | 338 | −0.30 (-0.56 to −0.04)SMD | 0.02 | 0% |
| Olanzapine | Weight gain | 2 | 411 | −0.73 (−0.93 to −0.52)SMD | <0.001 | 0% |
| ARI less favorable than | ||||||
| Risperidone | Discontinuation due to inefficacy | 3 | 562 | 1.72 (1.06 to 2.80)RR | 0.03 | 15% |
| Quetiapine | Akathisia | 3 | 260 | 1.42 (1.12 to 1.80)RR | 0.003 | 0% |
| Olanzapine | Use of anticholinergics | 3 | 445 | 2.28 (1.65 to 3.15)RR | <0.001 | 8% |
| Akathisia | 2 | 145 | 5.86 (1.83 to 18.73)RR | 0.003 | 0% | |
| Ziprasidone | Weight gain | 2 | 251 | 0.66 (0.40 to 0.91)SMD | <0.001 | 0% |
D2R dopamine D2 receptor, EPS extrapyramidal symptoms, SMD standardized mean difference, RR risk ratio.
aSMD less than 0 and RR less than 1 indicate aripiprazole is favored compared with other antipsychotics.